THOUSAND OAKS, Calif., April 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of Biomarker Assist™, a program to help more patients with metastatic (stage IV) non-small ...

Amgen's Nplate, which treats low ... They recruited 105 pathologists from 10 countries to take the course and to analyze tumor samples from 20 patients, both with and without AI assistance.

Amgen (NASDAQ:AMGN) and the Center for Social Sector Leadership at the University of California (UC), Berkeley’s Haas School of Business today announced a multi-year partnership to offer a ...

Amgen (NASDAQ: AMGN) today announced the launch of Biomarker Assist™, a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing.